Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is Phase 1/2 and is actively measuring dose-limiting toxicities and adverse events — what does that tell us about how much is still unknown about the safety of this drug combination, and how does that uncertainty compare to what we'd expect from standard first-line treatment for my kidney cancer?
2. 2Since the trial is no longer recruiting new participants, does that mean it's closed to me entirely, or are there related studies or successor trials testing similar immune and targeted therapy combinations that might still be open?
3. 3One of the main things this study is tracking is how often people have to stop treatment because of side effects — given my overall health and any conditions I already have, how would you assess my ability to handle a combination immunotherapy and targeted therapy regimen if those rates turn out to be significant?
4. 4The trial is measuring objective response rate as a key efficacy outcome — at this phase of the research, do we have any early or interim data suggesting whether this combination is showing meaningful tumor shrinkage compared to approved options I could pursue right now?
5. 5How does participating in a substudy like this one — which is part of a larger research program — affect my ability to switch to standard treatments or join other trials if this approach doesn't work for me?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.